A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

Abstract

PURPOSE: Epidermal growth factor receptor (EGFR) appears to play an important role in the pathogenesis of colorectal cancer. We have performed a Phase I/II study of the EGFR tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients in which serial biopsies were taken pre- and posttreatment to assess biological activity. EXPERIMENTAL DESIGN: Paired biopsies were obtained from colorectal cancer patients before and after treatment. …

Authors

Daneshmand M; Parolin DAE; Hirte HW; Major P; Goss G; Stewart D; Batist G; Miller WH; Matthews S; Seymour L

Journal

Clinical Cancer Research, Vol. 9, No. 7, pp. 2457–2464

Publication Date

7 2003

ISSN

1078-0432

Associated Experts

Holger Hirte

Professor Emeritus, Faculty of Health Sciences

Visit profile